Evidence map›Paper›PMID 40437602›Full record

ArticleOrphanet journal of rare diseases2025

Unlocking access: a comprehensive analysis of medicines accessibility for rare diseases in Thailand.

Siriwat Suwattanapreeda, Sanita Hirunrassamee, Chaoncin Sooksriwong, Kusawadee Maluangnon, Thirapich Chuachantra, Krissana Kuchaisit, Niti Osirisakul

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Siriwat SuwattanapreedaSomdet Chaopraya Institute of Psychiatry, 112 Somdetchaopraya Street, Klongsarn, Bangkok, 10600, Thailand.
Sanita HirunrassameeDrug Information and Consumer Protection Center, Center of Excellence in Pharmacy Practice and Management Research, Faculty of Pharmacy, Thammasat University, Khlong Luang District, Pathum Thani, Thailand. sanita_h@tu.ac.th.ORCID http://orcid.org/0009-0002-4165-3123
Chaoncin SooksriwongDrug Information and Consumer Protection Center, Center of Excellence in Pharmacy Practice and Management Research, Faculty of Pharmacy, Thammasat University, Khlong Luang District, Pathum Thani, Thailand.
Kusawadee MaluangnonDrug Information and Consumer Protection Center, Center of Excellence in Pharmacy Practice and Management Research, Faculty of Pharmacy, Thammasat University, Khlong Luang District, Pathum Thani, Thailand.
Thirapich ChuachantraMedicines Regulation Division, Food and Drug Administration, Ministry of Public Health, Nonthaburi, Thailand.
Krissana KuchaisitMedicines Regulation Division, Food and Drug Administration, Ministry of Public Health, Nonthaburi, Thailand.
Niti OsirisakulPharmacy Division, Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand.

Funding

the Health System Research Institute of Thailand 65-145
6 · The paper itself

Abstract

introductionIn Thailand, obtaining medicines for rare diseases presents significant challenges, with limited evidence highlighting these issues.

objectivesTo evaluate the accessibility of medicines and the extent of health insurance coverage for treatments of rare diseases in Thailand.

methodThis study utilized a thorough review of current health policies, drug registration database, and insurance coverage conditions. Additionally, procurement data from the Ministry of Finance was analyzed to verify the acquisition of medicines intended for the treatment of rare diseases.

resultsA review of the availability and procurement of medicines for rare diseases in Thailand revealed considerable limitations in both registration and accessibility. According to the International Rare Diseases Research Consortium, only 46.80% of their recommended medicines were registered in Thailand, and of these, just 22.93% were included in the national essential medicines list. Additionally, a review of the state's pharmaceutical procurement dataset over the past 5 years showed that merely 31.70% of these registered drugs had been purchased from suppliers for use in hospitals.

conclusionTo address these issues, the study recommended accelerating the approval process for rare disease medicines, expanding health insurance coverage, establishing financial support for patients, and creating a specific pricing policy for orphan drugs. Collaborative efforts among stakeholders were emphasized as crucial for improving access to essential medicines and enhancing treatment outcomes for patients with rare diseases in Thailand.

Indexed as

Health Services AccessibilityRare DiseasesHealth PolicyHumansOrphan Drug ProductionThailandAccessibilityHealth insurance coverageIRDiRCRare diseasesThe national essential medicines list

Identifiers

PMID40437602
PMCPMC12121248

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.